Some pre-clinical studies of solid tumors showed that, compared with monotherapy, the combination of PD-1 inhibitor and CTLA-4 inhibitor could produce synergistic effects and enhance their anti-tumor activity (51). The gene discussed is PDCD1; the disease is neoplasm.